Apatinib for Esophageal Squamous Cell Cancer After the Failure of Standard Treatment

Summary

We conduct the phase II clinical trial to further explore the efficacy and safety of Apatinib Mesylate in treating recurrent or metastatic esophageal squamous cell carcinoma after the failure of conventional treatments. An exploratory molecular marker analysis will be performed in order to find out the beneficial population of Apatinib Mesylate.

Timeline

Start

2016-08

Primary completion

2019-12

Completion

2022-12

Drugs

Indications